<!DOCTYPE html>

<html lang="en" data-theme="light">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Antiepileptic Drugs - Essentials of Medical Pharmacology</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap"
        rel="stylesheet">

    <link rel="stylesheet" href="../styles/main.css">

    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']],
                processEscapes: true,
                processEnvironments: true
            },
            svg: { fontCache: 'global' },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
            }
        };
    </script>

    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>

</head>

<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Floating TOC -->

    <nav class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span> Table of Contents
        </div>
        <ul class="floating-toc-list">
            <li><a href="#intro">Overview & Classification</a></li>
            <li><a href="#mechanism">General Mechanisms</a></li>
            <li><a href="#phenytoin">Phenytoin</a></li>
            <li><a href="#carbamazepine">Carbamazepine</a></li>
            <li><a href="#valproate">Valproate</a></li>
            <li><a href="#ethosuximide">Ethosuximide</a></li>
            <li><a href="#newer-drugs">Newer Antiepileptics</a></li>
            <li><a href="#choice">Choice of Drug</a></li>
            <li><a href="#status-epilepticus">Status Epilepticus</a></li>
            <li><a href="#case-study">Problem Directed Study</a></li>
        </ul>
    </nav>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>‚ö°</span>
                        <span>Topic 31</span>
                    </div>
                    <h1 class="document-title">Antiepileptic Drugs</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Central Nervous System</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>50 min read</span>
                        </div>
                    </div>
                </header>
                <main id="main-content" class="content-wrapper">
                    <!-- Section 1: Introduction -->
                    <section class="content-section" id="intro">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß†</span>
                                Overview & Classification
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Epilepsy is a group of disorders characterized by chronic recurrent, paroxysmal changes
                                in neurological function caused by abnormalities in electrical activity of the brain.
                                Antiepileptic drugs (AEDs) suppress seizures but do not cure the underlying pathology.
                            </p>

                            <h3>Classification</h3>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Chemical Class</th>
                                            <th>Drugs</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Barbiturates</strong></td>
                                            <td>Phenobarbitone</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Deoxybarbiturates</strong></td>
                                            <td>Primidone</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Hydantoins</strong></td>
                                            <td>Phenytoin, Fosphenytoin</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Iminostilbenes</strong></td>
                                            <td>Carbamazepine, Oxcarbazepine</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Succinimides</strong></td>
                                            <td>Ethosuximide</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Aliphatic carboxylic acids</strong></td>
                                            <td>Valproic acid (Sodium Valproate)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Benzodiazepines</strong></td>
                                            <td>Clonazepam, Diazepam, Lorazepam, Clobazam</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Newer Drugs</strong></td>
                                            <td>Lamotrigine, Gabapentin, Topiramate, Levetiracetam, Vigabatrin,
                                                Tiagabine, Lacosamide</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>

                    <!-- Section 2: Mechanisms -->
                    <section class="content-section" id="mechanism">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚öôÔ∏è</span>
                                General Mechanisms of Action
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>AEDs inhibit the generation of repetitive discharge or spread of electrical activity
                                through three main mechanisms:</p>

                            <div class="grid grid-3">
                                <div class="grid-item">
                                    <h4>1. Na<sup>+</sup> Channel Prolongation</h4>
                                    <p>Prolongation of the <strong>inactivated state</strong> of voltage-sensitive
                                        neuronal $Na^+$ channels. This prevents high-frequency firing (Use-dependent
                                        block).</p>
                                    <p><em>Drugs: Phenytoin, Carbamazepine, Valproate, Lamotrigine.</em></p>
                                </div>
                                <div class="grid-item">
                                    <h4>2. GABA Facilitation</h4>
                                    <p>Enhancement of GABA-mediated inhibitory transmission (opening of $Cl^-$
                                        channels).</p>
                                    <p><em>Drugs: Barbiturates, Benzodiazepines, Valproate, Vigabatrin (inhibits
                                            GABA-transaminase), Tiagabine (inhibits reuptake).</em></p>
                                </div>
                                <div class="grid-item">
                                    <h4>3. Ca<sup>2+</sup> Channel Inhibition</h4>
                                    <p>Inhibition of T-type $Ca^{2+}$ currents in thalamic neurons (specific for Absence
                                        Seizures).</p>
                                    <p><em>Drugs: Ethosuximide, Valproate.</em></p>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 3: Phenytoin -->
                    <section class="content-section" id="phenytoin">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Phenytoin (Diphenylhydantoin)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>A major antiepileptic drug, nonsedative in therapeutic range.</p>

                            <h3>Pharmacokinetics</h3>
                            <p>Absorption is slow. Highly protein bound (90%). Metabolism follows <strong>saturation
                                    kinetics (Zero Order)</strong> at therapeutic concentrations. Small increments in
                                dose can lead to disproportionate increase in plasma concentration and toxicity.</p>

                            <h3>Uses</h3>
                            <ul>
                                <li>Generalized Tonic-Clonic Seizures (GTCS).</li>
                                <li>Partial Seizures.</li>
                                <li>Status Epilepticus (Fosphenytoin is preferred).</li>
                                <li>Trigeminal Neuralgia (Carbamazepine is better).</li>
                                <li><em>Ineffective in Absence Seizures.</em></li>
                            </ul>

                            <div class="callout callout--danger">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ò£Ô∏è</span>
                                    <h4 class="callout-title">Adverse Effects</h4>
                                </div>
                                <div class="callout-content">
                                    <ul>
                                        <li><strong>Gum Hypertrophy:</strong> Common in children/adolescents. Minimized
                                            by oral hygiene.</li>
                                        <li><strong>Hirsutism & Acne:</strong> Cosmetic problems in young girls.</li>
                                        <li><strong>Fetal Hydantoin Syndrome:</strong> Teratogenic (Cleft lip/palate,
                                            microcephaly, digit hypoplasia).</li>
                                        <li><strong>Megaloblastic Anemia:</strong> Decreases folate absorption.</li>
                                        <li><strong>Osteomalacia:</strong> Increases Vitamin D metabolism.</li>
                                        <li><strong>Neurotoxicity:</strong> Ataxia, nystagmus, diplopia, vertigo
                                            (cerebellar-vestibular effects).</li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 4: Carbamazepine -->
                    <section class="content-section" id="carbamazepine">
                        <div class="section-header">
                            <div class="section-number">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ö°</span>
                                Carbamazepine
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Chemically related to tricyclic antidepressants. Mechanism similar to Phenytoin
                                (Na<sup>+</sup> channel block).</p>

                            <h3>Uses</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Partial Seizures (Complex/Simple):</strong> Drug of
                                    Choice.</li>
                                <li class="list-item"><strong>GTCS:</strong> First line drug.</li>
                                <li class="list-item"><strong>Trigeminal Neuralgia:</strong> Drug of Choice.</li>
                                <li class="list-item"><strong>Manic Depressive Illness (Bipolar):</strong> Acute mania
                                    and prophylaxis.</li>
                            </ul>

                            <h3>Adverse Effects</h3>
                            <p>Drowsiness, vertigo, ataxia. Water retention (ADH-like action - hyponatremia).
                                <strong>Enzyme Induction:</strong> Potent inducer of CYP450 (Autoinduction - induces its
                                own metabolism).</p>

                            <p><strong>Oxcarbazepine:</strong> Congener of carbamazepine. Less enzyme induction, less
                                toxic.</p>
                        </div>
                    </section>

                    <!-- Section 5: Valproate -->
                    <section class="content-section" id="valproate">
                        <div class="section-header">
                            <div class="section-number">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõ°Ô∏è</span>
                                Valproic Acid (Sodium Valproate)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>A broad-spectrum AED with multiple mechanisms: Na<sup>+</sup> channel block, T-type
                                Ca<sup>2+</sup> channel block, and increased GABA (inhibits GABA-transaminase).</p>

                            <h3>Uses</h3>
                            <ul>
                                <li><strong>Absence Seizures:</strong> Drug of choice (especially if co-existent GTCS).
                                </li>
                                <li><strong>Myoclonic & Atonic Seizures:</strong> Drug of Choice.</li>
                                <li><strong>GTCS and Partial Seizures:</strong> Highly effective.</li>
                                <li><strong>Bipolar Disorder & Migraine Prophylaxis.</strong></li>
                            </ul>

                            <div class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <h4 class="callout-title">Toxicity</h4>
                                </div>
                                <div class="callout-content">
                                    <ul>
                                        <li><strong>Hepatotoxicity:</strong> Rare but fatal fulminant hepatitis (more in
                                            children &lt; 2 yrs).</li>
                                        <li><strong>Teratogenicity:</strong> Neural tube defects (Spina bifida). Avoid
                                            in pregnancy.</li>
                                        <li><strong>Others:</strong> Weight gain, hair loss (alopecia), tremor,
                                            thrombocytopenia.</li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 6: Ethosuximide -->
                    <section class="content-section" id="ethosuximide">
                        <div class="section-header">
                            <div class="section-number">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üéØ</span>
                                Ethosuximide
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Mechanism:</strong> Selectively inhibits T-type $Ca^{2+}$ channels in thalamic
                                neurons.</p>
                            <p><strong>Use:</strong> Only for <strong>Absence Seizures</strong> (Petit mal). Not
                                effective for GTCS.</p>
                            <p><strong>Adverse Effects:</strong> GI distress, fatigue, headache.</p>
                        </div>
                    </section>

                    <!-- Section 7: Newer Drugs -->
                    <section class="content-section" id="newer-drugs">
                        <div class="section-header">
                            <div class="section-number">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üÜï</span>
                                Newer Antiepileptics
                            </h2>
                        </div>

                        <div class="content-card">
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Drug</th>
                                            <th>Key Features</th>
                                            <th>Major Use</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Lamotrigine</strong></td>
                                            <td>Blocks Na<sup>+</sup> and Ca<sup>2+</sup> channels. Broad spectrum.
                                                <strong>SJS risk</strong> (rash). Safe in pregnancy relative to
                                                Valproate.</td>
                                            <td>Refractory cases, Absence, Bipolar.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Levetiracetam</strong></td>
                                            <td>Binds to synaptic vesicle protein <strong>SV2A</strong>. Very safe, no
                                                drug interactions.</td>
                                            <td>Add-on for Partial/GTCS.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Topiramate</strong></td>
                                            <td>Multiple mechanisms (Na<sup>+</sup> block, GABA potentiation, AMPA
                                                antagonist). Causes cognitive slowing ("Dopamax").</td>
                                            <td>Refractory seizures, Migraine.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Gabapentin / Pregabalin</strong></td>
                                            <td>GABA analogues but bind to $\alpha_2\delta$ subunit of Ca<sup>2+</sup>
                                                channels.</td>
                                            <td>Neuropathic pain (Mainly).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Vigabatrin</strong></td>
                                            <td>Irreversible GABA-transaminase inhibitor. Visual field defects (Tunnel
                                                vision).</td>
                                            <td>Infantile spasms.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>

                    <!-- Section 8: Choice -->
                    <section class="content-section" id="choice">
                        <div class="section-header">
                            <div class="section-number">08</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚úÖ</span>
                                Choice of Drug
                            </h2>
                        </div>

                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Partial Seizures:</strong> Carbamazepine, Oxcarbazepine,
                                    Phenytoin, Lamotrigine, Levetiracetam.</li>
                                <li class="list-item"><strong>GTCS:</strong> Valproate, Carbamazepine, Lamotrigine,
                                    Phenytoin.</li>
                                <li class="list-item"><strong>Absence Seizures:</strong> Valproate, Ethosuximide,
                                    Lamotrigine. (Avoid Phenytoin/Carbamazepine - may worsen).</li>
                                <li class="list-item"><strong>Myoclonic Seizures:</strong> Valproate, Levetiracetam,
                                    Clonazepam.</li>
                                <li class="list-item"><strong>Febrile Seizures:</strong> Rectal Diazepam (intermittent).
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 9: Status Epilepticus -->
                    <section class="content-section" id="status-epilepticus">
                        <div class="section-header">
                            <div class="section-number">09</div>
                            <h2 class="section-title">
                                <span class="title-icon">üö®</span>
                                Status Epilepticus Management
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Continuous seizure activity for > 5 min. A medical emergency.</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><strong>General measures:</strong> Airway, Oxygen, Glucose (if
                                    hypoglycemic).</li>
                                <li class="list-item"><strong>First Line:</strong> <strong>Lorazepam</strong> (0.1 mg/kg
                                    IV) or Diazepam (10 mg IV). Lorazepam is preferred due to longer duration in brain.
                                </li>
                                <li class="list-item"><strong>Second Line:</strong> <strong>Fosphenytoin</strong> or
                                    Phenytoin IV infusion (loading dose). Prevents recurrence.</li>
                                <li class="list-item"><strong>Refractory:</strong> Phenobarbitone / Valproate /
                                    Levetiracetam IV.</li>
                                <li class="list-item"><strong>General Anaesthesia:</strong> Midazolam / Propofol /
                                    Thiopentone with intubation.</li>
                            </ol>
                        </div>
                    </section>

                    <!-- Section 10: Case Study -->
                    <section class="content-section" id="case-study">
                        <div class="section-header">
                            <div class="section-number">10</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü§î</span>
                                Problem Directed Study
                            </h2>
                        </div>

                        <div class="content-card">
                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üìù</span>
                                    <h4 class="callout-title">Case 30.1</h4>
                                </div>
                                <div class="callout-content">
                                    <p>A 12-year-old girl suffering from GTCS was treated with Phenytoin 50 mg twice
                                        daily. Seizures were controlled initially but recurred after 2 months. The dose
                                        was increased to 100 mg twice daily. Within 10 days she developed giddiness,
                                        ataxia, headache, and nystagmus.</p>
                                    <p><strong>(a) Cause of Toxicity:</strong> Phenytoin exhibits <strong>saturation
                                            kinetics (Zero Order)</strong>. At low doses, elimination is first order. As
                                        the enzymes get saturated at therapeutic levels, a small increase in dose (from
                                        100 to 200 mg/day) leads to a disproportionately large increase in plasma
                                        concentration, precipitating toxicity (cerebellar-vestibular signs).</p>
                                    <p><strong>(b) Management:</strong> Withhold the drug temporarily until symptoms
                                        subside. Restart at a slightly lower dose or measure plasma levels to adjust.
                                        Phenytoin requires careful dose titration in small increments.</p>
                                </div>
                            </div>
                        </div>
                    </section>

                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="topic-30-sedative-hypnotics.html"
                            class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Sedative-Hypnotics</div>
                        </a>

                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>31</span>
                                <span class="progress-separator">/</span>
                                <span>72</span>
                            </div>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 43%; role=" progressbar" aria-valuenow="43"
                                    aria-valuemin="0" aria-valuemax="100"></div>
                            </div>
                            <div class="progress-label">Topic Progress</div>
                        </div>

                        <a href="topic-32-antiparkinsonian.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Antiparkinsonian Drugs</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <script src="../js/theme.js"></script>

    <script src="../js/navigation.js"></script>

    <script src="../js/interactions.js"></script>

</body>

</html>